Clinical trials: Malignant Tumor
Solid Tumor
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting.
- Trial name
- NCT02590952
- Testing
- Epitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Hutchison Medipharma Limited
Locally Advanced Solid Tumor
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally…
- Trial name
- NCT04975958
- Testing
- AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Malignant Solid Tumor, Advanced Lung Cancer
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness.
- Conditions
- Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07110363
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Malignant Neoplasm
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
- Trial name
- NCT07600749
- Testing
- MK-4884
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).
- Trial name
- NCT02869243
- Testing
- hrBMP4
- Where
- 4 sites in Israel, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Stemgen
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Advanced Malignancies
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.
- Trial name
- NCT01930006
- Testing
- MGCD265
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Advanced Gastroenteropancreatic Neuroendocrine Tumor
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
- Trial name
- NCT05884255
- Testing
- Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide
- Where
- 2 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Malignant Neoplasm of Breast
Swedish Ibrance Registries Insights (SIRI)
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
- Trial name
- SIRI (NCT04654208)
- Testing
- palbociclib
- Where
- Sweden
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Solid Tumor
Study of SGR-3515 In Participants With Advanced Solid Tumors.
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
- Trial name
- NCT06463340
- Testing
- SGR-3515
- Where
- 14 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Schrödinger, Inc.
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
SPEARHEAD-3 Pediatric Study
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
- Conditions
- Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
- Trial name
- NCT05642455
- Testing
- Afamitresgene autoleucel
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- USWM CT, LLC
Solid Tumor
An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, single-center, dose-escalation study in patients with advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned for the study.
- Trial name
- NCT00657176
- Testing
- OPB-31121
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Advanced Solid Tumor
A Study of PM1015 in Patients With Advanced Solid Tumors
PM1015 is a specific antibody targeting CD73. This is a phase I study to evaluate the efficacy and safety of PM1015 in patients with advanced solid tumor.
- Trial name
- NCT05950815
- Testing
- CD73 Antigen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Biotheus Inc.
Solid Tumor
A Clinical Study on TILs for the Treatment of Advanced Solid Tumors
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients .
- Trial name
- NCT05971576
- Testing
- LM103
- Volunteers
- 20 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Advanced Malignant Solid Tumors
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
This is a multicenter, open-label, phase I clinical study employing a dose-escalation and cohort-expansion design to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in…
- Trial name
- NCT06717750
- Testing
- CSCJC3456 tablet
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Glioma, Astrocytoma
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
This clinical trial will study the safety and effectiveness of an engineered herpes virus, G207, administered directly into the brain of patients with recurrent brain cancer.
- Conditions
- Glioma, Astrocytoma, Glioblastoma
- Trial name
- NCT00028158
- Testing
- G207, an oncolytic virus
- Volunteers
- 65 people
- Sponsor
- MediGene
Solid Tumor
Dose Escalation Trial of BNT152+153 in Patients With Cancer
This is an open-label, multisite Phase I dose escalation, safety, pharmacokinetics (PK) and pharmacodynamics (PD) trial of BNT152+153 in various solid tumor indications.
- Trial name
- NCT04710043
- Testing
- BNT152, BNT153
- Where
- 7 sites in United States, Czechia
- Volunteers
- 86 people
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.